Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors.

Carracedo A, Egervari K, Salido M, Rojo F, Corominas JM, Arumi M, Corzo C, Tusquets I, Espinet B, Rovira A, Albanell J, Szollosi Z, Serrano S, Solé F.

Breast Cancer Res. 2009;11(2):402. doi: 10.1186/bcr2239. Epub 2009 Apr 21. No abstract available.

2.

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

Breast Cancer Res. 2009;11(1):R11. doi: 10.1186/bcr2230. Epub 2009 Feb 24.

3.

Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.

de Candia P, Akram M, Benezra R, Brogi E.

Hum Pathol. 2006 Aug;37(8):1032-41. Epub 2006 May 22.

PMID:
16867866
4.

The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.

Tong LC, Nelson N, Tsourigiannis J, Mulligan AM.

Am J Surg Pathol. 2011 Apr;35(4):545-52. doi: 10.1097/PAS.0b013e31820e6237.

PMID:
21358301
5.

Clinical and biological characteristics of breast cancer.

Kocic B, Filipovic S, Petrovic B, Mijalkovic D, Rancic N, Poultsidi A.

J BUON. 2010 Oct-Dec;15(4):660-7.

PMID:
21229626
6.

Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.

Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA.

J Clin Oncol. 2008 May 20;26(15):2473-81. doi: 10.1200/JCO.2007.13.6424. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472. Perez, Edith D [corrected to Perez, Edith A].

PMID:
18487567
7.
8.

Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.

Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H, Tang P.

Hum Pathol. 2008 Dec;39(12):1809-15. doi: 10.1016/j.humpath.2008.05.010. Epub 2008 Aug 19.

PMID:
18715613
9.

Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients.

Esteban JM, Felder B, Ahn C, Simpson JF, Battifora H, Shively JE.

Cancer. 1994 Sep 1;74(5):1575-83.

10.

Expression of the mismatch repair protein hMSH2 in carcinoma in situ and invasive cancer of the breast.

Bock N, Meden H, Regenbrecht M, Jünemann B, Wangerin J, Marx D.

Anticancer Res. 2000 Jan-Feb;20(1A):119-24.

PMID:
10769643
11.

Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.

Brower ST, Ahmed S, Tartter PI, Bleiweiss I, Amberson JB.

Ann Surg Oncol. 1995 Sep;2(5):440-4.

PMID:
7496840
13.

Prognostic value of the human antigen R (HuR) in human breast cancer: high level predicts a favourable prognosis.

Yuan Z, Sanders AJ, Ye L, Wang Y, Jiang WG.

Anticancer Res. 2011 Jan;31(1):303-10.

PMID:
21273615
14.

Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.

Webster LR, Lee SF, Ringland C, Morey AL, Hanby AM, Morgan G, Byth K, Mote PA, Provan PJ, Ellis IO, Green AR, Lamoury G, Ravdin P, Clarke CL, Ward RL, Balleine RL, Hawkins NJ.

Clin Cancer Res. 2008 Oct 15;14(20):6625-33. doi: 10.1158/1078-0432.CCR-08-0701.

15.
16.

Multicentric mammary carcinoma: evidence of monoclonal proliferation.

Middleton LP, Vlastos G, Mirza NQ, Eva S, Sahin AA.

Cancer. 2002 Apr 1;94(7):1910-6.

17.

Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers.

Feng W, Orlandi R, Zhao N, Carcangiu ML, Tagliabue E, Xu J, Bast RC Jr, Yu Y.

BMC Cancer. 2010 Jul 20;10:378. doi: 10.1186/1471-2407-10-378.

18.

Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.

Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O.

Hum Pathol. 2012 Jan;43(1):23-30. doi: 10.1016/j.humpath.2011.04.011. Epub 2011 Jul 20.

PMID:
21777944
19.

EGFR dependent expression of STAT3 (but not STAT1) in breast cancer.

Berclaz G, Altermatt HJ, Rohrbach V, Siragusa A, Dreher E, Smith PD.

Int J Oncol. 2001 Dec;19(6):1155-60.

PMID:
11713584
20.

The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion.

Petrović N, Mandušić V, Stanojević B, Lukić S, Todorović L, Roganović J, Dimitrijević B.

Med Oncol. 2014 Mar;31(3):867. doi: 10.1007/s12032-014-0867-x. Epub 2014 Feb 2.

PMID:
24488617

Supplemental Content

Support Center